EC
Euclidean Capital Portfolio holdings
AUM
$306M
This Quarter Return
+7.05%
1 Year Return
+16.69%
3 Year Return
+17.66%
5 Year Return
–
10 Year Return
–
AUM
$389M
AUM Growth
+$389M
(+241%)
Cap. Flow
+$268M
Cap. Flow
% of AUM
68.8%
Top 10 Holdings %
Top 10 Hldgs %
99.39%
Holding
12
New
2
Increased
4
Reduced
–
Closed
–
Top Buys
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$109M |
| 2 |
SPDR Gold Trust
GLD
|
$98.9M |
| 3 |
iShares MSCI India ETF
INDA
|
$53.5M |
| 4 |
RAPT Therapeutics
RAPT
|
$2.59M |
| 5 |
Foghorn Therapeutics
FHTX
|
$2.2M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 19.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
SPDR S&P 500 ETF Trust
SPY
$658B
| $109M | 28.05% |
+246,250
| New | +$109M |
|
|
2
iShares MSCI India ETF
INDA
$9.17B
| $106M | 27.23% |
2,425,144
+1,225,000
| +102% | +$53.5M |
|
|
3
SPDR Gold Trust
GLD
$107B
| $98.9M | 25.43% |
+555,000
| New | +$98.9M |
|
|
ME
4
DELISTED
23andMe Holding Co. Class A Common Stock
ME
| $17.9M | 4.61% |
10,243,122
| – | – |
|
5
PMV Pharmaceuticals
PMVP
$74.2M
| $15.9M | 4.09% |
2,545,242
+208,333
| +9% | +$1.3M |
|
|
6
Foghorn Therapeutics
FHTX
$286M
| $11.1M | 2.85% |
1,573,761
+312,500
| +25% | +$2.2M |
|
|
7
RAPT Therapeutics
RAPT
$188M
| $10.7M | 2.75% |
571,233
+138,333
| +32% | +$2.59M |
|
8
Alector
ALEC
$238M
| $5.9M | 1.51% |
980,894
| – | – |
|
9
Oric Pharmaceuticals
ORIC
$994M
| $5.8M | 1.49% |
747,550
| – | – |
|
10
Tenaya Therapeutics
TNYA
$184M
| $5.38M | 1.38% |
915,705
| – | – |
|
|
NGM
11
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $1.93M | 0.5% |
746,674
| – | – |
|
12
Surrozen
SRZN
$104M
| $442K | 0.11% |
802,963
| – | – |
|